Fig. 6: The FDA-approved drug Osimertinib binds with Mtb EF-Tu and inhibits Mycobacterium growth. | Communications Biology

Fig. 6: The FDA-approved drug Osimertinib binds with Mtb EF-Tu and inhibits Mycobacterium growth.

From: Structural insights of the elongation factor EF-Tu complexes in protein translation of Mycobacterium tuberculosis

Fig. 6

a, b Thermal unfolding curves and unfolding transition midpoints of EF-Tu and EF-Tu/Osimertinib were detected by the Nano-DSF method. c–f Osimertinib did not affect E. coli growth, but significantly inhibited the growth of M. smegmatis, Mtb H37Ra, and M. bovis BCG strains. Different concentrations of Osimertinib were added to the bacterial strains, and cell densities were detected at different times (c–e). After treatment with varying concentrations of Osimertinib, the BCG strains were diluted 100 or 1000 times, and the numbers of colonies were calculated (f). g The MST result showed that Osimertinib is bound with EF-Tu in vitro. h The in silico modeling structure of EF-Tu and Osimertinib complex. EF-Tu was shown in a cartoon model. Osimertinib was shown in a stick model. The error bars represented the standard deviations (SD). *P < 0.05, **P < 0.01, ns no significance.

Back to article page